Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

NCT01122875 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01122875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01122875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2010
Completion date
May 31, 2012
Enrollment
14 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma